Skip to main content
SpringerLink
Log in

What are SNPs and haplotypes and how will they help us manage the prevention of adult cancer?

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Human genetic variation data are now publicly available on a large scale, from public and private discovery efforts. Datasets from the International Haplotype Map Consortium and Perlegen Sciences provide a level of knowledge about human genetic variation that is unprecedented. In combination with novel high-throughput genotyping technologies, these new resources will allow cancer prevention investigators to identify in a more precise way which genetic subsets of patients are likely to benefit most from chemoprevention and screening interventions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Lynch HT, Riley BD, Weissman SM, et al.: Hereditary nonpolyposis colorectal carcinoma (HNPCC) and HNPCClike families: problems in diagnosis, surveillance, and management. Cancer 2004, 100:53–64. Excellent review on the use of genetics to improve cancer screening and survival.

    Article  PubMed  Google Scholar 

  2. Wiesner GL, Daley D, Lewis S, et al.: A subset of familial colorectal neoplasia kindreds linked to chromosome 9q22.2-31. 2 Proc Natl Acad Sci U S A 2003, 100:12961–12965.

    Article  CAS  Google Scholar 

  3. Hinds DA, Stuve LL, Nilsen GB, et al.: Whole-genome patterns of common DNA variation in three human populations. Science 2005, 307:1072–1079. An important original work that describes a state-of-the-art analysis of human genetic variation.

    Article  PubMed  CAS  Google Scholar 

  4. Collins FS: Genome research: the next generation. Cold Spring Harb Symp Quant Biol 2003, 68:49–54.

    Article  PubMed  CAS  Google Scholar 

  5. Crawford DC, Akey DT, Nickerson DA: The patterns of natural variation in human genes. Annu Rev Genomics Hum Genet 2005 May 19; [Epub ahead of print].

  6. Crawford DC, Nickerson DA: Definition and clinical importance of haplotypes. Annu Rev Med 2005, 56:303–320. State-of-the-art review on SNPs and haplotypes.

    Article  PubMed  CAS  Google Scholar 

  7. Evans WE, McLeod HL: Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med 2003, 348:538–549. This review summarizes in an excellent manner the use of SNPs in pharmocogenentics/pharmacogenomics.

    Article  PubMed  CAS  Google Scholar 

  8. Weng WK, Levy R: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003, 21:3940–3947.

    Article  PubMed  CAS  Google Scholar 

  9. Evans WE: Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit 2004, 26:186–191.

    Article  PubMed  CAS  Google Scholar 

  10. Marsh S, McLeod HL: Pharmacogenetics of irinotecan toxicity. Pharmacogenomics 2004, 5:835–843.

    Article  PubMed  CAS  Google Scholar 

  11. Fukunaga AK, Marsh S, Murry DJ, et al.: Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway. Pharmacogenomics 2004, J4:307–314.

    Google Scholar 

  12. McLeod HL, King CR, Marsh S: Application of pharmacogenomics in the individualization of chemotherapy for gastrointestinal malignancies. Clin Colorectal Cancer 2004, 4(Suppl 1):S43-S47.

    Article  PubMed  CAS  Google Scholar 

  13. Marsh S, McLeod HL: Cancer pharmacogenetics. Br J Cancer 2004, 90:8–11.

    Article  PubMed  CAS  Google Scholar 

  14. Keller JJ, Giardiello FM: Chemoprevention strategies using NSAIDs and COX-2 inhibitors. Cancer Biol Ther 2003, 2:S140-S149.

    PubMed  CAS  Google Scholar 

  15. Annie Yu HJ, Lin KM, Ota DM, Lynch HT: Hereditary nonpolyposis colorectal cancer: preventive management. Cancer Treat Rev 2003, 29:461–470.

    Article  PubMed  Google Scholar 

  16. Graaf MR, Beiderbeck AB, Egberts AC, et al.: The risk of cancer in users of statins. J Clin Oncol 2004, 22:2388–2394. An excellent meta-analysis of the chemopreventive effects of statins in multiple cancer types.

    Article  PubMed  CAS  Google Scholar 

  17. Poynter JN, Gruber SB, Higgins PD, et al.: Statins and the risk of colorectal cancer. N Engl J Med 2005, 352:2184–2192.

    Article  PubMed  CAS  Google Scholar 

  18. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ: C-reactive protein and the risk of incident colorectal cancer. JAMA 2004, 291:585–590.

    Article  PubMed  CAS  Google Scholar 

  19. Lipkin SM, Rozek LS, Rennert G, et al.: The MLH1 D132H variant is associated with susceptibility to sporadic colorectal cancer. Nat Genet 2004, 36:694–699.

    Article  PubMed  CAS  Google Scholar 

  20. Siest G, Jeannesson E, Berrahmoune H, et al.: Pharmacogenomics and drug response in cardiovascular disorders. Pharmacogenomics 2004, 5:779–802.

    Article  PubMed  CAS  Google Scholar 

  21. Chasman DI, Posada D, Subrahmanyan L, et al.: Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004, 291:2821–2827.

    Article  PubMed  CAS  Google Scholar 

  22. de Groot E, Jukema JW, van Boven AJ, et al.: (1995) Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study. Am J Cardiol 1995, 76:40C-46C.

    Article  PubMed  Google Scholar 

  23. Packham C, Robinson J, Morris J, et al.: Statin prescribing in Nottingham general practices: a cross-sectional study. J Public Health Med 1999, 21:60–64.

    Article  PubMed  CAS  Google Scholar 

  24. van Hout BA, Simoons ML: Cost-effectiveness of HMG coenzyme reductase inhibitors: whom to treat? Eur Heart J 2001, 22:751–761.

    Article  PubMed  Google Scholar 

  25. Puccetti L, Pasqui AL, Pastorelli M, et al.: Time-dependent effect of statins on platelet function in hypercholesterolaemia. Eur J Clin Invest 2002, 32:901–908.

    Article  PubMed  CAS  Google Scholar 

  26. Ozaki K, Ohnishi Y, Iida A, et al.: Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002, 32:650–654.

    Article  PubMed  CAS  Google Scholar 

  27. Undevia SD, Gomez-Abuin G, Ratain MJ: Pharmacokinetic variability of anticancer agents. Nat Rev Cancer 2005, 5:447–458.

    Article  PubMed  CAS  Google Scholar 

  28. Sklar P: Principles of haplotype mapping and potential applications to attention-deficit/hyperactivity disorder. Biol Psychiatry 2005, 57:1357–1366.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Medicine, Divisions of Hematology-Oncology and Epidemiology, University of California, Irvine, 839 Medical Sciences Court, 2nd Floor, Sprague Hall-Lab 250, 92697, Irvine, CA, USA

    Steven M. Lipkin MD, PhD

Authors
  1. Jonathan L. Velasquez BA
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven M. Lipkin MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Velasquez, J.L., Lipkin, S.M. What are SNPs and haplotypes and how will they help us manage the prevention of adult cancer?. Curr Oncol Rep 7, 475–479 (2005). https://doi.org/10.1007/s11912-005-0013-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-005-0013-1

Keywords

Search

Navigation